Straits Times Index
3,334.28 -4.66 (-0.14%) Nikkei
38,490.17 -347.29 (-0.89%) Hang Seng
18,438.58 -5.53 (-0.03%) FTSE 100
8,248.60 +16.56 (+0.20%) Bitcoin USD
71,300.57 +2,275.30 (+3.30%) CMC Crypto 200
1,481.84 +8.10 (+0.55%)
OGN Jan 2025 40.000 call
| Previous close | 0.0800 |
| Open | 0.0500 |
| Bid | 0.0000 |
| Ask | 3.6000 |
| Strike | 40.00 |
| Expiry date | 2025-01-17 |
| Day's range | 0.0800 - 0.0800 |
| Contract range | N/A |
| Volume | |
| Open interest | 6 |
ZacksOrganon (OGN) Just Overtook the 20-Day Moving Average
When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?
Business WireEuropean Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14
SHANGHAI, China & JERSEY CITY, N.J., May 24, 2024--European Medicines Agency validates Organon and Henlius marketing authorization filings for Prolia and Xgeva (denosumab) biosimilar candidate HLX14.
Business WireOrganon Announces Pricing of $1.0 Billion Senior Notes Offering
JERSEY CITY, N.J., May 08, 2024--Organon (NYSE: OGN) ("Organon"), a global healthcare company with a focus on women’s health, announced today that it, together with Organon Foreign Debt Co-Issuer B.V., a direct wholly-owned subsidiary of Organon, as co-issuer (the "Co-Issuer" and, together with Organon, the "Companies"), have priced an offering of $500 million of 6.750% senior secured notes due 2034 (the "Secured Notes") and $500 million of 7.875% senior unsecured notes due 2034 (the "Unsecured
